

## MDC/CCL22

Catalog # PVGS1460

## **Product Information**

Primary Accession 000626-1
Species Human

**Sequence** Gly25-Gln93, expressed with an N-terminal Met

**Purity** > 95% as analyzed by SDS-PAGE

**Endotoxin Level** 

**Biological Activity** The EC<sub>50</sub> value of human MDC/CCL22(69aa)on Ca<sup>2+</sup> mobilization assay in

CHO-K1/Gα15/hCCR4 cells (human Gα15 and human CCR4 stably expressed in

CHO-K1 cells) is less than 1.0 ☐g/ml.

**Expression System** E. coli

**Formulation** Lyophilized after extensive dialysis against PBS.

**Reconstitution** It is recommended that this vial be briefly centrifuged prior to opening to

bring the contents to the bottom. Reconstitute the lyophilized powder in

ddH<sub>2</sub>O or PBS up to 100 □g/ml.

**Storage & Stability** Upon receiving, this product remains stable for up to 6 months at lower than

-70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw

cycles.

## **Additional Information**

Target Background

Macrophage-Derived/CCL22 Chemokine (MDC), also known as stimulated T cell chemotactic protein (STCP1), is a CC chemokine initially isolated from clones of monocytederived macrophages. CCL22 is one of several Cys-Cys (CC) cytokine genes clustered on the q arm of chromosome 16. CCL22 shows

chemotactic activity for natural killer cells, chronically activated T

lymphocytes, monocytes and dendritic cells. CCL22 has mild chemotactic activity for primary activated T lymphocytes and no chemoattractant activity for neutrophils, eosinophils or resting T lymphocytes. CCL22 may also be involved in certain aspects of activated T lymphocyte physiology, such astrafficking activated T lymphocytes to inflammatory sites. CCL22 interacts

with the cell surface chemokine receptor CCR4.

## **Protein Information**

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.